Psychedelic medicines trial to begin

Psychedelic therapy trial takes serious look at effectiveness

Latest in Health
THERAPY GAP: Mind Medicine Australia co-founder Tania de Jong says there is a "desperate need" for innovation in the mental health sector.

THERAPY GAP: Mind Medicine Australia co-founder Tania de Jong says there is a "desperate need" for innovation in the mental health sector.

Aa

Clinical trial to test 200 participants to assess usefulness of magic mushrooms, ecstasy.

Aa

While psychedelic medicines might bring to mind images of a hippies living free and easy in the '60s and '70s, today they are the subject of serious clinical research into alternative ways of treating mental illness.

A clinical trial, part-funded by the mental health charity and advocacy group Mind Medicine Australia, will begin later this year with up to 200 participants.

It will study the brain activity of participants after their exposure to psychedelic medicines.

Half the participants will be administered a single medical dose of MDMA (ecstasy), with the rest exposed to a single medical dose of psilocybin - the hallucinogen in "magic" mushrooms.

All will be screened to ensure there are no contra-indications or risk factors that could prevent their participation.

The project will be carried out according to the National Statement on Ethical Conduct in Human Research (2018), produced by the National Health and Medical Research Council.

Mind Medicine Australia says strong evidence exists to support the safety and clinical effectiveness of MDMA-assisted psychotherapy for PTSD, and psilocybin for depression.

The trial aims to determine whether brain activity changes following exposure to the drugs, and to assess potential changes in mood, personality, beliefs and social engagement after exposure that might relate to neural changes.

Monarch Mental Health is sponsoring the clinical trial. Principal investigators include psychiatrist Paul Fitzgerald, co-founder of TMS Clinics Australia.

"The results of the study will inform us as to whether these substances have an effect on brain activity related to cognitive and emotional processes which continues after the medicine session," Professor Fitzgerald said.

"They may also provide information that can help explain how these substances have their clinical effects."

Tania de Jong started Mind Medicine Australia with her husband Peter Hunt in 2019 seeking to alleviate suffering caused by mental illness. This includes developing safe and effective psychedelic-assisted therapies to cure a range of mental illnesses.

"There is a desperate need for innovation in the mental health sector and these treatments have achieved outstanding results in overseas trials after just two to three sessions in combination with a short course of psychotherapy," Ms de Jong said.

"We now have the potential to help people suffering from major classes of mental illness such as depression, post-traumatic stress disorder and potentially anorexia and other eating disorders, OCD, dementia and a range of addictions."

She says attitudes about psychedelic medicines are changing.

A recent poll commissioned by Mind Medicine Australia reported that more than 60 per cent of Australians support increased access to psychedelic medicines.

The "sentiment poll" was designed to gauge public feeling about access to psychedelic medicines in medically controlled environments to treat some forms of mental illness.

Essential Research polled more than 1000 Australians aged 18-plus across a range of demographics.

It found that:

  • 67 per cent agreed that the terminally ill should have the choice to use psychedelic-assisted therapy to ease end-of-life distress
  • 63 per cent agreed that people with mental illness should have the choice to access psychedelic-assisted therapy in medically controlled environments
  • 63 per cent agreed that psychedelic-assisted therapy should be an alternative option for people with mental illness who have not had success with other treatments
  • 61 per cent agreed that it should be made easier for researchers to conduct more clinical trials to test the effectiveness of psychedelic-assisted therapy in treating mental illness
  • 60 per cent agreed the difference between medical and recreational use of psychedelic substances should be recognised in law
  • 11 per cent had heard of psychedelic-assisted therapy and what it involved
  • 19 per cent had heard of psychedelic-assisted therapy but did not know what it involved.

Ms de Jong welcomed the findings: "Australians are ready and support change. It's time for the politicians, political parties and federal, state and territory governments to follow suit and act with urgency to avoid further avoidable suffering and suicide."

Aa